Navigation Links
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Date:11/18/2011

TARRYTOWN, N.Y., Nov. 18, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, for the treatment of patients with neovascular (wet) Age-related Macular Degeneration (AMD) at a recommended dose of 2 milligrams (mg) every four weeks (monthly) for the first 12 weeks, followed by 2 mg every eight weeks (2 months).

The approval of EYLEA was granted under a Priority Review, a designation that is given to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.  This approval was based upon the results of two Phase 3 clinical studies.  In these studies, EYLEA dosed every eight weeks, following three initial monthly injections, was clinically equivalent to the standard of care, Lucentis® (ranibizumab injection) dosed every four weeks, as measured by the primary endpoint of maintenance of visual acuity (less than 15 letters of vision loss on an eye chart) over 52 weeks.  The most common adverse reactions (frequency of 5% or more) reported in patients receiving EYLEA were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and increased intraocular pressure.  The adverse event profile was similar to that seen with ranibizumab.

"The approval of EYLEA offers a much needed new treatment option for patients with wet AMD," said Jeffrey Heier, M.D., a clinical ophthalmologist and retinal specialist at Ophthalmic Consultants of Boston, Assistant Professor of Ophthalmology at Tufts School of Medicine, and Chair of the Steering Committee for the VIEW 1 trial.
"EYLEA offers the potential of achieving the efficacy we've come to expect from current anti-VEGF agents, but with less frequent injections and no monitoring requirements.  This may reduce the need for cos
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
2. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
3. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
4. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
5. Regeneron Reports Second Quarter 2011 Financial and Operating Results
6. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
7. Trading in Regeneron Common Stock Halted
8. Regeneron Reports First Quarter 2011 Financial and Operating Results
9. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
11. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... -- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... H. Burbank , Chief Executive Officer, will present at the ... on Wednesday, March 11 th at 3:50 ... be made available at http://ir.nxstage.com  at the time ... NxStage Medical, Inc. (Nasdaq: NXTM ) is a ...
(Date:3/4/2015)... WASHINGTON , March 4, 2015  Mail-service ... consumers, employers and government health plans ... research released by the Pharmaceutical Care Management Association ... specialty drugs offers one of the easiest ways ... CEO Mark Merritt . "Policymakers should resist ...
(Date:3/4/2015)...   Aratana Therapeutics, Inc . (NASDAQ: ... licensing, development and commercialization of innovative biopharmaceutical products for ... the Barclays Global Healthcare Conference to be ... Hotel in Miami , FL.  ... and Chief Executive Officer of Aratana Therapeutics, will provide ...
Breaking Medicine Technology:NxStage to Present at the Barclays Capital Global Healthcare Conference 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Illinois Employers, Consumers and Public Programs by $11.8 Billion 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2
... Corporation, a Nevada corporation ("MusclePharm" or the "Company") (OTCBB: ... to announce MusclePharm,s preliminary financial results for the third ... preliminary basis, the Company expects unaudited gross revenues for ... $5,700,000, an increase of 305% as compared to gross ...
... PRUSSIA, Pa., Oct. 10, 2011 Medical Alarm Concepts ... first fully-monitored medical alarm system that allows the user ... announced that it has officially launched its new television ... (HM3) one of the leading producers of infomercials and ...
Cached Medicine Technology:MusclePharm Announces Preliminary Third Quarter 2011 Results 2MusclePharm Announces Preliminary Third Quarter 2011 Results 3Medical Alarm Concepts Accelerates Return of MediPendant™ to Airwaves - Well Financed Nationwide Campaign Moving Ahead 2Medical Alarm Concepts Accelerates Return of MediPendant™ to Airwaves - Well Financed Nationwide Campaign Moving Ahead 3Medical Alarm Concepts Accelerates Return of MediPendant™ to Airwaves - Well Financed Nationwide Campaign Moving Ahead 4
(Date:3/5/2015)... Hinton, W.Va. (PRWEB) March 05, 2015 ... looming, but rather here—and it’s a crisis that is ... , In order to stay on top of ... are partnering with PracticeLink to meet face-to-face with physicians ... Career Advancement Workshop and Job Fair series. , Physician ...
(Date:3/4/2015)... March 05, 2015 Understanding China’s New ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/UnderstandingChinaMDRegs ... revamped regulations for medical devices in China. , ... devices — research and development, approval, manufacturing, distribution, and ... those currently in development as well as those that ...
(Date:3/4/2015)... 04, 2015 Imagine No Malaria’s 2014 World ... Care2 Innovator Award , an honor given to nonprofit causes ... the Nonprofit Technology Conference (NTC15) in Austin, Texas. ... Methodist Church in Austin, was on hand for the presentation; ... No Malaria. , Imagine No Malaria was one of five ...
(Date:3/4/2015)... The Asia-Pacific phthalic anhydride market is ... by 2019, at a CAGR of 5.9% during ... Browse through the TOC of Asia-Pacific Phthalic Anhydride ... segments, with the help of various tables and ... is a derivative of phthalic acid, which is ...
(Date:3/4/2015)... March 04, 2015 When people talk about ... top artists spread across numerous genres, the Houston Rodeo ... conversation. Each night during the annual livestock show and rodeo, ... to the other activities being held at the event. The ... of performers that will try and get the festival its ...
Breaking Medicine News(10 mins):Health News:Physician Shortage Crisis Worsening 2Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 2Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 3Health News:Imagine No Malaria Receives Care2 Innovator Award 2Health News:Imagine No Malaria Receives Care2 Innovator Award 3Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 2Health News:The Asia-Pacific Ohthalic Anhydride Market is Estimated to Reach $5,632.8 Million by 2019 - A Report by MicroMarket Monitor 3Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 2Health News:Cheap Houston Rodeo Tickets: Ticket Down Slashes Houston Rodeo Tickets for John Legend, Pitbull, Alan Jackson, Tim McGraw, Zac Brown Band, Fall Out Boy & Miranda Lambert 3
... ... ... , ... ...
... , ... ... , , , , ... ...
... ... ... , ... , , ...
... bone-building drugs used to prevent and treat osteoporosis may be at ... researchers published today in the British Journal of Cancer. , ... Fosamax, Boniva and Zomita, for more than two years had a ... did not, according to lead author Polly Newcomb, Ph.D., M.P.H., head ...
... who used them lost weight, lowered heart disease risk, ... Workplace wellness programs help employees lose weight and reduce ... , U.S. researchers followed 757 hospital workers who took ... focused on diet and exercise. Data on the participants, ...
... ... ... , ... , , , ...
Cached Medicine News:Health News:Pelosi Remarks at Press Availability on Health Insurance Reform 2Health News:Pelosi Remarks at Press Availability on Health Insurance Reform 3Health News:Pelosi Remarks at Press Availability on Health Insurance Reform 4Health News:Pelosi Remarks at Press Availability on Health Insurance Reform 5Health News:KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs 2Health News:KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs 3Health News:KV Pharmaceutical Subsidiary Pleads Guilty to Two Felonies Regarding Oversized Drugs 4Health News:Philadelphia Phillies Host Tug McGraw Foundation to Raise Awareness for Brain Tumors 2Health News:Philadelphia Phillies Host Tug McGraw Foundation to Raise Awareness for Brain Tumors 3Health News:Common osteoporosis drugs are associated with a decrease in risk of breast cancer 2Health News:Workplace Wellness Programs Work 2Health News:Star of TV's The Doctors Helping Put Smiles on Faces of Needy Children in India 2Health News:Star of TV's The Doctors Helping Put Smiles on Faces of Needy Children in India 3
... description: For loading gel sample slots 0.4 ... tips). Uses disposable, flexible, autoclavable, precision tapered ... plunger does not contact sample. Includes ... O-rings, and one plastic spacer. ...
... Analyzer reduces the time, cost, and complexity ... sensitivity and advanced polymers enable you to ... Multiple automation features decrease costly human errors. ... compromising your results. , Perform a wide ...
The Pipetman Large-Volume Kit includes two large-volume pipettes conveniently packaged with filters and tips at an exceptional price....
... this unique offer, you can ... application. Pipetman P2 and P10 ... reagents, and P100 is perfect ... Filter Tips, which are especially ...
Medicine Products: